Harter, P, Mouret-Reynier, M A, Pignata, S, Cropet, C, González-Martín, A, Bogner, G, Fujiwara, K, Vergote, I, Colombo, N, Nøttrup, T J, Floquet, A, El-Balat, A, Scambia, G, Guerra Alia, E M, Fabbro, M, Schmalfeldt, B, Hardy-Bessard, A C, Runnebaum, I, Pujade-Lauraine, E & Ray-Coquard, I 2022, ' Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial ', Gynecologic Oncology, vol. 164, no. 2, pp. 254-264 . https://doi.org/10.1016/j.ygyno.2021.12.016 Gynecologic Oncology Gynecologic Oncology, 2022, 164 (2), pp.254-264. ⟨10.1016/j.ygyno.2021.12.016⟩